Centogene and agios expand partnership for clinical development of pyrukynd® (mitapivat) to treat children with rare blood disease

Working together on the world's first treatment that targets the underlying causes of pyruvate kinase (“pk”) deficiency in children under the age of 18 working together on the world's first treatment that targets the underlying causes of pyruvate kinase (“pk”) deficiency in children under the age of 18
CNTG Ratings Summary
CNTG Quant Ranking